Affinage

YES1

Tyrosine-protein kinase Yes · UniProt P07947

Length
543 aa
Mass
60.8 kDa
Annotated
2026-04-28
100 papers in source corpus 22 papers cited in narrative 22 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

YES1 is a Src family non-receptor tyrosine kinase with distinct signaling roles in endothelial biology, immune cell function, viral maturation, and oncogenesis. YES1 is activated downstream of receptor tyrosine kinases (FGFR-1β, EphA2) and G-protein-coupled receptors (BLT1), and phosphorylates substrates including YAP/TAZ—promoting their nuclear accumulation and transcriptional activity to drive tumorigenesis—and ANXA2 at Tyr24, facilitating cancer cell invasion (PMID:35041461, PMID:31391186, PMID:33941853, PMID:16631103, PMID:15749899). Its activity is regulated by Ca²⁺-dependent association with inhibitory cellular proteins, by membrane anchoring through the SMIM30 peptide, and by scaffolding via mislocalized Scribble, which stabilizes the active-conformation kinase and channels signaling through YAP1-Y357 phosphorylation (PMID:8246968, PMID:32461121, PMID:33730553). YES1 gene amplification is a clinically relevant resistance mechanism to EGFR and HER2 inhibitors in lung and breast cancers, operating primarily through mTOR and YAP/TAZ signaling axes (PMID:29875142, PMID:31856375, PMID:31166114).

Mechanistic history

Synthesis pass · year-by-year structured walk · 11 steps
  1. 1986 High

    Establishing YES1's identity as a Src family tyrosine kinase resolved the question of what enzymatic activity c-yes encoded and placed it within the broader SFK family.

    Evidence Molecular cloning and nucleotide sequencing of human c-yes cDNA

    PMID:3526330

    Open questions at the time
    • No information on specific substrates or biological functions
    • Regulatory mechanisms unknown
  2. 1993 High

    The discovery that intracellular Ca²⁺ elevation inactivates YES1 through association with inhibitory proteins—independent of PKC and distinct from c-Src regulation—established a unique regulatory mechanism for this kinase.

    Evidence In vitro kinase assays, gradient sedimentation, co-immunoprecipitation, and reconstitution with Ca²⁺-supplemented extracts

    PMID:8246968

    Open questions at the time
    • Identity of the Ca²⁺-dependent inhibitory binding partners not determined
    • Physiological context of Ca²⁺-mediated YES1 inactivation not established
  3. 1995 Medium

    Demonstrating elevated YES1 kinase activity in high-risk colonic adenomas provided the first evidence linking YES1 activation to early-stage human neoplasia.

    Evidence In vitro tyrosine kinase activity assay on human colonic adenoma tissue samples

    PMID:7806032

    Open questions at the time
    • Causal versus correlative relationship not established
    • Downstream substrates in colon tissue not identified
  4. 2005 High

    Two studies revealed non-redundant biological functions of YES1: it is specifically required for West Nile virus particle maturation and egress (distinct from Src), and it is activated downstream of BLT1 receptor endocytosis to mediate neutrophil degranulation, demonstrating YES1-specific roles in viral biology and innate immunity.

    Evidence siRNA knockdown, pharmacological inhibition (PP1/PP2), endoglycosidase H digestion, electron microscopy, dominant-negative dynamin transfection

    PMID:15749899 PMID:16140770

    Open questions at the time
    • Direct YES1 substrates in viral trafficking and degranulation pathways not identified
    • Whether YES1 kinase activity or scaffolding function mediates virus maturation unclear
  5. 2006 High

    Identifying FGFR-1β as a direct activator of YES1 via its SH2 domain, and showing YES1 is specifically required for VEGF-induced endothelial migration (not tube formation), established YES1 as a non-redundant SFK in angiogenic signaling.

    Evidence Co-immunoprecipitation, SH2/SH3 domain binding assays, selective siRNA knockdown of individual SFKs, endothelial functional assays

    PMID:16400523 PMID:16631103

    Open questions at the time
    • Direct endothelial substrates of YES1 beyond cortactin activation not mapped
    • In vivo angiogenesis phenotype of YES1 loss not tested
  6. 2018 High

    A transposon mutagenesis screen revealed YES1 amplification as a mechanism of acquired resistance to all three generations of EGFR inhibitors, establishing YES1 as a clinically actionable bypass kinase in EGFR-mutant lung cancer.

    Evidence Transposon mutagenesis screen, siRNA knockdown, pharmacological inhibition, clinical genomic sequencing

    PMID:29875142

    Open questions at the time
    • Precise downstream signaling route from YES1 to EGFR-bypass not fully delineated at this point
    • Therapeutic window of YES1 inhibition in patients not established
  7. 2019 High

    Two studies defined the major downstream effector pathways of YES1 in cancer: mTOR signaling drives YES1-dependent NSCLC growth and metastasis, while YES1 regulates YAP1 nuclear translocation and transcriptional activity—establishing the YES1–YAP1 axis as a druggable oncogenic module.

    Evidence CRISPR/Cas9 KO, patient-derived xenografts, shRNA, YES1-specific inhibitor CH6953755, YAP1 nuclear localization assays

    PMID:31166114 PMID:31391186

    Open questions at the time
    • Whether mTOR and YAP1 axes are parallel or convergent downstream of YES1 not resolved
    • Clinical efficacy of YES1-specific inhibitors not yet demonstrated
  8. 2020 Medium

    The SMIM30 micropeptide was shown to promote YES1 membrane anchoring and activation, linking a non-coding RNA-encoded peptide to SFK regulation and downstream MAPK signaling in hepatocellular carcinoma; separately, YES1 amplification was identified as a resistance mechanism to HER2-targeted neratinib.

    Evidence Co-immunoprecipitation, membrane fractionation, MAPK pathway analysis; resistant cell line generation, siRNA/dasatinib rescue experiments

    PMID:31856375 PMID:32461121

    Open questions at the time
    • Mechanism by which SMIM30 facilitates membrane anchoring (direct lipid modification assistance or scaffolding) not clear
    • Whether SMIM30-YES1 interaction is direct or requires intermediary proteins
  9. 2021 High

    Three key mechanistic advances clarified YES1 signaling: mislocalized Scribble scaffolds active-conformation YES1 to phosphorylate YAP1-Y357; EphA2 activates YES1 which phosphorylates ANXA2-Y24 to drive gastric cancer invasion; and YES1 phosphorylates OCT1 to regulate hepatic transporter activity.

    Evidence HaloTag genome engineering with HaloPROTAC degradation and AP-MS; site-directed mutagenesis (ANXA2-Y24F) rescue experiments with in vivo models; phospho-proteomics with metabolomics validation in mice

    PMID:33730553 PMID:33790797 PMID:33941853

    Open questions at the time
    • Full substrate repertoire of YES1 remains unmapped
    • Structural basis of Scribble–YES1 interaction not determined
    • Whether OCT1 phosphorylation is relevant in human drug metabolism not confirmed
  10. 2022 High

    Transgenic expression of activated Yes in mouse hepatocytes demonstrated sufficiency for liver tumorigenesis with YAP/TAZ as required downstream effectors, while YES1 inhibition in SCLC revealed a role in DNA repair and replication, broadening YES1's functional repertoire beyond YAP signaling.

    Evidence Hepatocyte-specific transgenic mice with epistasis experiments; siRNA/shRNA plus pharmacological inhibition in SCLC organoids and xenografts with DNA repair pathway analysis

    PMID:35041461 PMID:35988891

    Open questions at the time
    • Direct YES1 substrates in the DNA repair/replisome pathway not identified
    • Whether YAP/TAZ-independent oncogenic functions contribute to hepatocarcinogenesis not resolved
  11. 2024 Medium

    ACSL3 was identified as a negative regulator of YES1 activation, suppressing Tyr419 phosphorylation and thereby inhibiting YAP1 nuclear translocation, adding a metabolic enzyme to the network controlling YES1 activity.

    Evidence Co-immunoprecipitation, Tyr419 phosphorylation analysis, gain- and loss-of-function assays in breast cancer models

    PMID:38953696

    Open questions at the time
    • Whether ACSL3 directly dephosphorylates YES1 or acts via a phosphatase is unknown
    • Mechanism by which a lipid-CoA ligase regulates a tyrosine kinase not elucidated
    • Single-lab finding awaits independent confirmation

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key unresolved questions include the full substrate repertoire of YES1, the structural basis for its regulation by Scribble and ACSL3, clinical validation of YES1-specific inhibitors, and the extent to which YES1 non-kinase (scaffolding) functions contribute to its biology.
  • No comprehensive substrate identification study (e.g., analog-sensitive allele) has been performed
  • No crystal structure of YES1 in complex with any regulatory partner exists
  • Clinical trial data for YES1-selective inhibitors not yet available

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 6 GO:0016740 transferase activity 4
Localization
GO:0005829 cytosol 1 GO:0005886 plasma membrane 1
Pathway
R-HSA-162582 Signal Transduction 7 R-HSA-1643685 Disease 4
Partners
ACSL3ANXA2EPHA2FGFR1SCRIBSMIM30SRCYAP1

Evidence

Reading pass · 22 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1986 YES1 (c-yes/SYN) encodes a protein-tyrosine kinase structurally similar to v-yes and human c-Src, identifying it as a member of the Src family of tyrosine kinases Molecular cloning and nucleotide sequence analysis of cDNA Proceedings of the National Academy of Sciences of the United States of America High 3526330
1993 c-Yes kinase is inactivated by elevation of intracellular calcium through a Ca2+-dependent association with specific cellular proteins that inhibit its kinase activity; this mechanism is distinct from c-Src regulation and independent of protein kinase C In vitro kinase activity assays, gradient sedimentation, co-immunoprecipitation, in vitro reconstitution with Ca2+-supplemented cell extracts Molecular and cellular biology High 8246968
1995 c-Yes tyrosine kinase activity is elevated in colonic adenomas at greatest risk for cancer (villous architecture, large size, severe dysplasia), demonstrating YES1 activation as an early event in colonic neoplasia In vitro protein-tyrosine kinase activity assay (enolase phosphorylation and autophosphorylation) on human tissue samples Gastroenterology Medium 7806032
2005 c-Yes (but not c-Src) is specifically required for maturation and egress of West Nile virus particles; YES1 knockdown reduces virus yield and prevents viral envelope glycoprotein E trafficking beyond the endoplasmic reticulum without affecting viral RNA or protein synthesis RNA interference knockdown of c-Yes, endoglycosidase H digestion, electron microscopy, SFK inhibitor PP2 treatment Journal of virology High 16140770
2005 YES1 (Yes kinase) is activated downstream of BLT1 receptor endocytosis following LTB4 stimulation in human neutrophils, and this activation is required for neutrophil degranulation; BLT1 endocytosis is necessary for Yes kinase activation In vitro kinase activity assays, dominant-negative dynamin transfection, pharmacological inhibition (PP1), endocytosis inhibitors Journal of immunology High 15749899
2006 c-Yes is the predominant Src family kinase in endothelial cells; the FGFR-1beta isoform (but not FGFR-1alpha) directly associates with and activates c-YES via its SH2 domain recognizing phospho-FGFR-1beta, leading to cortactin activation and SFK-dependent cord formation Co-immunoprecipitation, SH2/SH3 domain binding assays, stable transfection of FGFR isoforms, kinase activity assays, in vitro cord formation Archives of biochemistry and biophysics High 16631103
2006 YES1 and Src play distinct roles in VEGF-mediated endothelial cell events: YES1 is specifically required for VEGF-induced cell migration, while Fyn (not YES1) is required for tube formation; all three SFKs are required for VEGF mitogenic signaling RNA interference (selective siRNA knockdown of Src, Fyn, and Yes individually), cell migration, tube formation, and proliferation assays Angiogenesis High 16400523
2013 YES1 is a druggable kinase target; homology models of YES1 were generated in active (DFG-in) and inactive conformations, and inhibitors identified by HTS preferentially bind the active conformation High-throughput enzymatic activity screen, cell-based survival assays, homology modeling and inhibitor docking Bioorganic & medicinal chemistry letters Medium 23787099
2013 YES1 is a direct target of miR-145 in colon cancer cells; miR-145 binds the 3'-UTR of YES1 mRNA to suppress its expression Microarray-based target identification, seed site enrichment analysis, direct validation by luciferase reporter assay PloS one Medium 20098684
2018 YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors in EGFR-mutant lung adenocarcinoma; clones with transposon insertions activating YES1 expression exhibit resistance to all three generations of EGFR inhibitors and sensitivity to YES1 inhibition Transposon mutagenesis screen, siRNA knockdown, pharmacological inhibition, clinical genomic sequencing Proceedings of the National Academy of Sciences of the United States of America High 29875142
2019 YES1 effects on NSCLC growth and metastasis are mainly driven by mTOR signaling; YES1 overexpression induces metastatic spread and CRISPR/Cas9 depletion of YES1 significantly reduces tumor growth and metastasis CRISPR/Cas9 genetic depletion, in vivo tumor models, patient-derived xenografts, signaling pathway analysis American journal of respiratory and critical care medicine High 31166114
2019 YES1 regulates YAP1 transcriptional activity by controlling its nuclear translocation and serine phosphorylation; a specific YES1 kinase inhibitor (CH6953755) blocks this regulation and exerts antitumor activity in YES1-amplified cancers shRNA knockdown, YES1-specific kinase inhibitor CH6953755, YAP1 nuclear translocation assays, phosphorylation analysis, in vitro and in vivo tumor models Cancer research High 31391186
2020 The peptide SMIM30 (encoded by lncRNA LINC00998) promotes membrane anchoring of SRC/YES1 non-receptor tyrosine kinases, leading to their phosphorylation and activation of the downstream MAPK signaling pathway in HCC RIP-seq, cell-based functional assays, co-immunoprecipitation, membrane fractionation, MAPK pathway analysis Journal of hepatology Medium 32461121
2020 YES1 activation induces acquired resistance to neratinib (HER2-targeted therapy) in HER2-amplified breast and lung cancer cells; YES1 amplification was identified in neratinib-resistant lines and dasatinib or siRNA-mediated YES1 inhibition restored sensitivity, with combined dasatinib+neratinib treatment downregulating HER2, AKT and MAPK signaling Establishment of resistant cell lines, siRNA knockdown, pharmacological inhibition with dasatinib, in vivo combination treatment, Western blot signaling analysis Cancer science High 31856375
2021 YES1 phosphorylates the organic cation transporter OCT1 at tyrosine residues, regulating its hepatic uptake activity; pharmacological YES1 inhibition with dasatinib modulates hepatic OCT1 function in mice as shown by metabolomics Phospho-proteomics screen, genetic and pharmacological YES1 inhibition, metabolomics (isobutyryl L-carnitine as biomarker), mouse models Frontiers in pharmacology Medium 33790797
2021 Mislocalized Scribble scaffolds the active (open αC-helix-in) conformation of YES1 in epithelial cancer cells, promoting YAP1-Y357 phosphorylation and YAP1 nuclear localization; junction-localized Scrib does not recruit active YES1 HaloTag genome engineering, Snail-induced mislocalization, HaloPROTAC degradation, Halo-ligand affinity purification mass spectrometry, YAP1 phosphorylation assays Cell chemical biology High 33730553
2021 EphA2 activates YES1, which then phosphorylates ANXA2 at Tyr24, causing ANXA2 activation and increased nuclear distribution, driving gastric cancer invasion and metastasis; reexpression of WT but not Tyr24F mutant ANXA2 rescues YES1-induced invasion Co-immunoprecipitation, kinase activity assays, site-directed mutagenesis (Tyr24F), knockdown/overexpression, in vitro invasion/migration assays, mouse tumor models Oncogene High 33941853
2022 YES1 tyrosine kinase phosphorylates YAP and TAZ (YAP/TAZ), promoting their nuclear accumulation and transcriptional activity in HCC; transgenic expression of activated Yes in mouse hepatocytes is sufficient to induce liver tumorigenesis, and YAP/TAZ are required effectors downstream of Yes Genetic (transgenic mouse, hepatocyte-specific expression) and pharmacological interventions, YAP/TAZ phosphorylation analysis, nuclear localization assays, epistasis experiments Science signaling High 35041461
2022 YES1 is druggable in SCLC; YES1-inhibited cells reveal alterations in replisome and DNA repair processes that confer sensitivity to irradiation; CH6953755 and dasatinib induce antitumor activity in organoid and xenograft models Genetic depletion (siRNA/shRNA), pharmacological inhibition, organoid formation, patient-derived xenografts, DNA repair pathway analysis Journal of thoracic oncology Medium 35988891
2022 YES1 linc01133 sponges miR-145-5p to upregulate YES1, which promotes YAP1 nuclear translocation and upregulation of cell cycle regulators CDK4, CDK6, and cyclin D1, driving G1-S phase transition in gastric cancer Dual-luciferase reporter assay, miRNA target validation, YES1 knockdown/overexpression, YAP1 nuclear localization assays, in vitro and in vivo tumor models Cell death & disease Medium 35017464
2024 ACSL3 interacts with YES1 and suppresses YES1 activation through phosphorylation at Tyr419; decreased active YES1 inhibits YAP1 nuclear colocalization and transcriptional complex formation in breast cancer cells Co-immunoprecipitation, phosphorylation analysis (Tyr419), gain- and loss-of-function assays, nuclear localization assays, in vitro and in vivo models Cancer biology & medicine Medium 38953696
2024 YES1 undergoes post-translational modifications including lipidation and nitrosylation that modulate its catalytic activity, subcellular localization, and substrate binding affinity Review summarizing experimental findings on YES1 PTMs from multiple studies International journal of molecular sciences Low 38338729

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2008 Expression of Yes-associated protein in common solid tumors. Human pathology 482 18703216
1986 yes-related protooncogene, syn, belongs to the protein-tyrosine kinase family. Proceedings of the National Academy of Sciences of the United States of America 243 3526330
2020 Peptide SMIM30 promotes HCC development by inducing SRC/YES1 membrane anchoring and MAPK pathway activation. Journal of hepatology 179 32461121
2013 Wnt your brain be inflamed? Yes, it Wnt! Trends in molecular medicine 139 23312954
2010 MicroRNA-145 targets YES and STAT1 in colon cancer cells. PloS one 139 20098684
2016 Long noncoding RNA H19 competitively binds miR-17-5p to regulate YES1 expression in thyroid cancer. The FEBS journal 131 27093644
2017 miR-140-5p suppresses the proliferation, migration and invasion of gastric cancer by regulating YES1. Molecular cancer 123 28818100
2018 High mobility group protein B1 controls liver cancer initiation through yes-associated protein -dependent aerobic glycolysis. Hepatology (Baltimore, Md.) 114 29149457
2016 Hedgehog regulates yes-associated protein 1 in regenerating mouse liver. Hepatology (Baltimore, Md.) 101 26970079
2015 Are Platelets Cells? And if Yes, are They Immune Cells? Frontiers in immunology 101 25750642
2004 Is HIV-1 RNA dimerization a prerequisite for packaging? Yes, no, probably? Retrovirology 101 15345057
2015 Yes-Associated Protein is up-regulated by mechanical overload and is sufficient to induce skeletal muscle hypertrophy. FEBS letters 93 25959868
1983 Brain-blood barrier? Yes and no. Proceedings of the National Academy of Sciences of the United States of America 91 6580650
2011 Yes-associated protein regulation of adaptive liver enlargement and hepatocellular carcinoma development in mice. Hepatology (Baltimore, Md.) 84 21391223
2012 Overexpression of Yes-associated protein confers doxorubicin resistance in hepatocellullar carcinoma. Oncology reports 76 23232767
2005 The Src family kinase c-Yes is required for maturation of West Nile virus particles. Journal of virology 69 16140770
2021 EphA2-YES1-ANXA2 pathway promotes gastric cancer progression and metastasis. Oncogene 67 33941853
2023 The beneficial role of autophagy in multiple sclerosis: Yes or No? Autophagy 63 37712858
2013 Yes-associated protein (YAP) promotes cell survival by inhibiting proapoptotic dendrin signaling. The Journal of biological chemistry 63 23667252
1995 Elevated c-yes tyrosine kinase activity in premalignant lesions of the colon. Gastroenterology 63 7806032
2012 Yes-associated protein 1 is activated and functions as an oncogene in meningiomas. Molecular cancer research : MCR 61 22618028
2014 Yes-associated protein 1 (YAP1) promotes human gallbladder tumor growth via activation of the AXL/MAPK pathway. Cancer letters 60 25218593
2019 YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib. American journal of respiratory and critical care medicine 59 31166114
2019 YES1 Is a Targetable Oncogene in Cancers Harboring YES1 Gene Amplification. Cancer research 51 31391186
2018 YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. Proceedings of the National Academy of Sciences of the United States of America 51 29875142
2017 Dual roles of yes-associated protein (YAP) in colorectal cancer. Oncotarget 49 29088905
2007 Arguing for the motion: yes, RAGE is a receptor for advanced glycation endproducts. Molecular nutrition & food research 48 17854009
2013 The role and clinical significance of YES-associated protein 1 in human osteosarcoma. International journal of immunopathology and pharmacology 46 23527718
2006 Src, Fyn and Yes play differential roles in VEGF-mediated endothelial cell events. Angiogenesis 46 16400523
2016 Role of Yes-associated protein in cancer: An update. Oncology letters 45 27698789
2014 Yes-associated protein (YAP) modulates oncogenic features and radiation sensitivity in endometrial cancer. PloS one 45 24972085
2022 β-Catenin Sustains and Is Required for YES-associated Protein Oncogenic Activity in Cholangiocarcinoma. Gastroenterology 43 35489428
2022 YES1: A Novel Therapeutic Target and Biomarker in Cancer. Molecular cancer therapeutics 43 35732509
2015 Expression of Yes-associated protein (YAP) in metastatic breast cancer. International journal of clinical and experimental pathology 43 26617849
2014 The Yes-associated protein controls the cell density regulation of Hedgehog signaling. Oncogenesis 43 25111861
2014 Yes! Sex matters: sex, the brain and blood pressure. Current hypertension reports 39 24929952
2005 Involvement of BLT1 endocytosis and Yes kinase activation in leukotriene B4-induced neutrophil degranulation. Journal of immunology (Baltimore, Md. : 1950) 39 15749899
2020 Circular RNA circ-CDYL sponges miR-1180 to elevate yes-associated protein in multiple myeloma. Experimental biology and medicine (Maywood, N.J.) 38 32321304
2017 Promoter methylation of yes-associated protein (YAP1) gene in polycystic ovary syndrome. Medicine 38 28079802
2016 IQGAP1 Binds to Yes-associated Protein (YAP) and Modulates Its Transcriptional Activity. The Journal of biological chemistry 38 27440047
2018 Do Memory B Cells Form Secondary Germinal Centers? Yes and No. Cold Spring Harbor perspectives in biology 37 28320754
2015 Netrin-1 exerts oncogenic activities through enhancing Yes-associated protein stability. Proceedings of the National Academy of Sciences of the United States of America 37 26039999
2017 MiR-199a suppresses prostate cancer paclitaxel resistance by targeting YES1. World journal of urology 36 29204706
2018 Yes-associated protein promotes the abnormal proliferation of psoriatic keratinocytes via an amphiregulin dependent pathway. Scientific reports 35 30323299
2013 The hippo-yes association protein pathway in liver cancer. Gastroenterology research and practice 35 23986776
2011 Yes-associated protein is involved in proliferation and differentiation during postnatal liver development. American journal of physiology. Gastrointestinal and liver physiology 35 22194415
2018 MicroRNA-140 attenuates myocardial ischemia-reperfusion injury through suppressing mitochondria-mediated apoptosis by targeting YES1. Journal of cellular biochemistry 34 30259997
1993 Inactivation of c-Yes tyrosine kinase by elevation of intracellular calcium levels. Molecular and cellular biology 33 8246968
2019 β-Catenin and Yes-Associated Protein 1 Cooperate in Hepatoblastoma Pathogenesis. The American journal of pathology 32 30794807
2020 Circ_0057553/miR-515-5p Regulates Prostate Cancer Cell Proliferation, Apoptosis, Migration, Invasion and Aerobic Glycolysis by Targeting YES1. OncoTargets and therapy 30 33177837
2020 Progesterone, via yes-associated protein, promotes cardiomyocyte proliferation and cardiac repair. Cell proliferation 29 33047378
2015 miR-203 downregulates Yes-1 and suppresses oncogenic activity in human oral cancer cells. Journal of bioscience and bioengineering 29 25910964
2020 Congenital nephrotic syndrome: is early aggressive treatment needed? Yes. Pediatric nephrology (Berlin, Germany) 28 32377865
2013 Identification of potent Yes1 kinase inhibitors using a library screening approach. Bioorganic & medicinal chemistry letters 28 23787099
2022 miR-133a targets YES1 to reduce cisplatin resistance in ovarian cancer by regulating cell autophagy. Cancer cell international 27 35012539
2010 Identification of the YES1 Kinase as a Therapeutic Target in Basal-Like Breast Cancers. Genes & cancer 27 21779430
2022 Linc01133 contributes to gastric cancer growth by enhancing YES1-dependent YAP1 nuclear translocation via sponging miR-145-5p. Cell death & disease 26 35017464
2018 Inhibition of yes-associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model. Journal of cellular and molecular medicine 26 29575527
2018 Yes-associated protein enhances proliferation and attenuates sensitivity to cisplatin in human gastric cancer cells. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 25 30021363
2014 Expression of Yes-associated protein in cervical squamous epithelium lesions. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 25 25304677
2006 Yes-associated protein (YAP65) in relation to Smad7 expression in human pancreatic ductal adenocarcinoma. International journal of molecular medicine 25 16596258
2021 Yes-Associated Protein (Yap) Is Up-Regulated in Heart Failure and Promotes Cardiac Fibroblast Proliferation. International journal of molecular sciences 23 34200497
2019 CCN1-Yes-Associated Protein Feedback Loop Regulates Physiological and Pathological Angiogenesis. Molecular and cellular biology 23 31262999
2022 Matrix Mechanotransduction via Yes-Associated Protein in Human Lamina Cribrosa Cells in Glaucoma. Investigative ophthalmology & visual science 22 35015027
2021 Influence of YES1 Kinase and Tyrosine Phosphorylation on the Activity of OCT1. Frontiers in pharmacology 22 33790797
2020 YES1 activation induces acquired resistance to neratinib in HER2-amplified breast and lung cancers. Cancer science 22 31856375
2020 Yes-Associated Protein 1: Role and Treatment Prospects in Orthopedic Degenerative Diseases. Frontiers in cell and developmental biology 22 33178690
2022 YES1 Is a Druggable Oncogenic Target in SCLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 21 35988891
2021 Hippo/yes-associated protein signaling functions as a mechanotransducer in regulating vascular homeostasis. Journal of molecular and cellular cardiology 21 34547259
2017 Yes-associated protein 1 promotes the differentiation and mineralization of cementoblast. Journal of cellular physiology 21 28688217
2008 Does COMT val158met affect behavioral phenotypes: yes, no, maybe? Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 21 18923401
2020 Long non-coding TUG1 accelerates prostate cancer progression through regulating miR-128-3p/YES1 axis. European review for medical and pharmacological sciences 20 32016963
2001 Adenosine in the treatment of stroke: yes, maybe, or absolutely not? Expert opinion on investigational drugs 20 11281813
2021 Scribble sub-cellular localization modulates recruitment of YES1 to regulate YAP1 phosphorylation. Cell chemical biology 19 33730553
2018 Does the use of indirect calorimetry change outcome in the ICU? Yes it does. Current opinion in clinical nutrition and metabolic care 19 29341970
2015 Up-regulation of microRNA-210 inhibits proliferation of hepatocellular carcinoma cells by targeting YES1. World journal of gastroenterology 19 26676187
2023 The yes-associated protein (YAP) is associated with resistance to anti-GD2 immunotherapy in neuroblastoma through downregulation of ST8SIA1. Oncoimmunology 18 37554309
2019 MicroRNA-133a inhibits the proliferation of non-small cell lung cancer by targeting YES1. Oncology letters 18 31807185
2015 Role of Yes-associated protein 1 in gliomas: pathologic and therapeutic aspects. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 18 25750037
2013 Is rituximab effective in childhood nephrotic syndrome? Yes and no. Pediatric nephrology (Berlin, Germany) 18 23820888
2008 Does sildenafil reverse the adverse effects of ischemia on ischemic colon anastomosis: yes, 'no'. International journal of surgery (London, England) 18 19022713
2006 Alternatively spliced FGFR-1 isoforms differentially modulate endothelial cell activation of c-YES. Archives of biochemistry and biophysics 18 16631103
2019 Time is on the Immune System's Side, Yes it is. The Yale journal of biology and medicine 17 31249483
2016 DO SYMPTOMS OF ILLNESS SERVE SIGNALING FUNCTIONS? (HINT: YES). The Quarterly review of biology 17 27405223
2013 The Src family kinases: distinct functions of c-Src, Yes, and Fyn in the liver. Biomolecular concepts 17 25436571
2010 Transcriptional profiling of the nucleus pulposus: say yes to notochord. Arthritis research & therapy 17 20497604
1990 Is the dry eye contact lens wearer at risk? Yes. Cornea 17 2189682
2020 MiR-133 Targets YES1 and Inhibits the Growth of Triple-Negative Breast Cancer Cells. Technology in cancer research & treatment 16 32462982
2017 MiR-361 targets Yes-associated protein (YAP) mRNA to suppress cell proliferation in lung cancer. Biochemical and biophysical research communications 16 28837805
2024 ACSL3 regulates breast cancer progression via lipid metabolism reprogramming and the YES1/YAP axis. Cancer biology & medicine 15 38953696
2023 A New Player in the Mechanobiology of Deep Fascia: Yes-Associated Protein (YAP). International journal of molecular sciences 15 37895068
2022 Locally Performed HRD Testing for Ovarian Cancer? Yes, We Can! Cancers 15 36612041
2021 Circ-ZNF124 downregulation inhibits non-small cell lung cancer progression partly by inactivating the Wnt/β-catenin signaling pathway via mediating the miR-498/YES1 axis. Anti-cancer drugs 15 33186139
2020 Inhibition of yes-associated protein dephosphorylation prevents aggravated periodontitis with occlusal trauma. Journal of periodontology 15 33094479
2019 Deficiency of Yes-Associated Protein Induces Cataract in Mice. Aging and disease 15 31011480
2006 Striatal D2 receptors and LTD: yes, but not where you thought they were. Neuron 15 16675388
2022 Signaling by the tyrosine kinase Yes promotes liver cancer development. Science signaling 14 35041461
2021 Yes, MAM! Molecular & cellular oncology 14 34616865
2020 Liver cancer stem cells as a hierarchical society: yes or no? Acta biochimica et biophysica Sinica 14 32490517
2024 Emerging Roles of YES1 in Cancer: The Putative Target in Drug Resistance. International journal of molecular sciences 13 38338729